Who is sponsoring NCT01915173?

NCT01915173 is sponsored by Beth Israel Deaconess Medical Center.

What condition does NCT01915173 study?

NCT01915173 studies Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia.

What drugs are being tested in NCT01915173?

Interventions: Supplement, Placebo, Expanded Interview, Standard Interview.

What is the status of NCT01915173?

NCT01915173 is currently COMPLETED.

Last reviewed 2017-02-24 · How we verify

Response to Supplement and Placebo in GERD

NCT01915173 NA COMPLETED Results posted

The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux disease (GERD). This study is designed as a pilot trial to assess safety and feasibility and to provide preliminary estimates of effect sizes.

Details

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	NA
Status	COMPLETED
Enrolment	24
Start date	2013-06
Completion	2014-04

Conditions

Gastroesophageal Reflux Disease (GERD)
Heartburn
Dyspepsia

Interventions

Supplement
Placebo
Expanded Interview
Standard Interview

Primary outcomes

Safety - Number of Participants Experiencing a Serious Adverse Event — 2 week follow-up
Serious adverse events (as defined by the FDA) are events that are potentially life-threatening or result in death, hospitalization, an emergency room visit, disability or permanent damage, a congenital abnormality, require intervention to prevent permanent impairment, or seriously jeopardizes a patient's health.

Countries

United States